Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant Cancers
纳米粒子联合递送 RNAi 和化疗治疗多重耐药癌症
基本信息
- 批准号:8164302
- 负责人:
- 金额:$ 13.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-01 至 2013-07-31
- 项目状态:已结题
- 来源:
- 关键词:ABCB1 geneAddressAdverse effectsAntineoplastic AgentsCellsCessation of lifeCharacteristicsChargeChemotherapy-Oncologic ProcedureClinicalCombined Modality TherapyDevelopmentDiseaseDrug CombinationsDrug Delivery SystemsDrug resistanceEmulsionsEngineeringEvaluationGene SilencingGenerationsHybridsIn VitroIndividualKineticsLeadLibrariesLigandsLipidsMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMediatingMicroRNAsMolecularMulti-Drug ResistanceNanotechnologyOutcomeP-GlycoproteinPharmaceutical PreparationsPhasePhysiologicalPolymersPropertyProteinsRNA InterferenceRPS6KA5 geneResearchResistanceSmall Interfering RNASurfaceSystemTaxane CompoundTechnologyTestingTherapeuticTherapeutic IndexTransferrinXenograft Modelaptamerbasebiocompatible polymerbiodegradable polymercancer cellchemotherapeutic agentchemotherapycombination cancer therapycontrolled releasecytotoxicdensitydesignimprovedin vivointerestnanoparticlenanoparticulatenanoscalenanosystemsnanotherapeuticparticlereceptorself assemblyspatiotemporalstemtargeted deliverytaxaneuptake
项目摘要
DESCRIPTION (provided by applicant): A critical barrier to effective cancer chemotherapy is the development of multidrug resistance (MDR) in cancer cells. The broad and long-term objective of this project is to develop advanced nanomedicinal approaches for the treatment of multidrug resistant cancers. We believe that nanomedicinal therapy, which can simultaneously deliver RNAi therapeutics to suppress MDR and chemotherapeutic agents to induce the death of cancer cells, will be of particular interest in addressing the challenge of MDR in cancer chemotherapy. Specifically, we will design and develop nanoparticulate platforms for the effective co-delivery of RNAi and anti-cancer agents with a synergistic drug ratio to taxane-resistant lung and prostate cancer cells, by using biodegradable and biocompatible polymers and lipids. The contribution of different drug-resistant proteins to cancer MDR will be compared. The physicochemical properties of the nanoparticles will also be optimized to overcome the physiological barriers in vivo, while keeping the co-delivery of RNAi and chemotherapy safe and effective. Furthermore, in the R00 independent phase, the nanoparticulate platform will be precisely engineered to control the temporal release of individual agents and to achieve targeted drug delivery. We hypothesize that the spatiotemporal controlled delivery of nanotherapeutics can maximize the desired effects of RNAi and anti-cancer agents for multidrug resistant cancers, while minimizing their toxic side effects. If successful, this project will lay the groundwork for wider applications of the nanotechnology-based targeted combination therapy for cancer and other diseases.
PUBLIC HEALTH RELEVANCE: In this project we will use double-emulsion technology combined with self-assembly for nanoparticle synthesis. A library of the hybrid lipid-polymer nanoparticles will be formulated by tuning particle surface characteristics, components, drug loading/ratio, drug release profile, and targeting ligand density to optimize the co-delivery of RNAi and anti-cancer agents for multidrug resistant cancers (e.g., lung and prostate cancers). This nanoparticulate platform may be useful for the generation of versatile vehicles for targeted delivery of diverse drug combinations for a variety of therapeutic applications.
描述(由申请人提供):有效癌症化疗的一个关键障碍是癌细胞中多药耐药性(MDR)的发展。该项目的广泛和长期目标是开发用于治疗多药耐药癌症的先进纳米医学方法。我们相信,纳米医学治疗,它可以同时提供RNAi治疗抑制MDR和化疗药物诱导癌细胞死亡,将在解决癌症化疗MDR的挑战特别感兴趣。具体来说,我们将设计和开发纳米颗粒平台,通过使用可生物降解和生物相容的聚合物和脂质,以协同药物比例将RNAi和抗癌剂有效地共同递送到紫杉烷耐药的肺癌和前列腺癌细胞。比较不同耐药蛋白对肿瘤MDR的贡献。纳米颗粒的物理化学性质也将得到优化,以克服体内的生理障碍,同时保持RNAi和化疗的共同递送安全有效。此外,在R 00独立阶段,纳米颗粒平台将被精确地设计以控制单个药剂的时间释放并实现靶向药物递送。我们假设纳米治疗剂的时空控制递送可以最大限度地提高RNAi和抗癌剂对多药耐药癌症的预期效果,同时最大限度地减少其毒副作用。如果成功,该项目将为基于纳米技术的靶向联合治疗癌症和其他疾病的更广泛应用奠定基础。
公共卫生相关性:在这个项目中,我们将使用双乳液技术结合自组装的纳米颗粒合成。将通过调节颗粒表面特征、组分、药物负载/比率、药物释放曲线和靶向配体密度来配制杂合脂质-聚合物纳米颗粒的文库,以优化RNAi和抗癌剂对多药耐药癌症(例如,肺癌和前列腺癌)。该纳米颗粒平台可用于产生多功能载体,用于靶向递送用于各种治疗应用的多种药物组合。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(3)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jinjun Shi其他文献
Jinjun Shi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jinjun Shi', 18)}}的其他基金
A New Lipid Nanoparticle Technology Enabling Long-acting mRNA Therapy
新型脂质纳米颗粒技术实现长效 mRNA 治疗
- 批准号:
10669826 - 财政年份:2023
- 资助金额:
$ 13.27万 - 项目类别:
Long-Acting RNAi Therapy for Atherosclerosis and Insulin Resistance
长效 RNAi 治疗动脉粥样硬化和胰岛素抵抗
- 批准号:
10424582 - 财政年份:2021
- 资助金额:
$ 13.27万 - 项目类别:
Long-Acting RNAi Therapy for Atherosclerosis and Insulin Resistance
长效 RNAi 治疗动脉粥样硬化和胰岛素抵抗
- 批准号:
10631236 - 财政年份:2021
- 资助金额:
$ 13.27万 - 项目类别:
Long-Acting RNAi Therapy for Atherosclerosis and Insulin Resistance
长效 RNAi 治疗动脉粥样硬化和胰岛素抵抗
- 批准号:
10277786 - 财政年份:2021
- 资助金额:
$ 13.27万 - 项目类别:
Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant Cancers
纳米粒子联合递送 RNAi 和化疗治疗多重耐药癌症
- 批准号:
8689250 - 财政年份:2013
- 资助金额:
$ 13.27万 - 项目类别:
Nanoparticle Co-delivery of RNAi and Chemotherapy for Multidrug Resistant Cancers
纳米粒子联合递送 RNAi 和化疗治疗多重耐药癌症
- 批准号:
8707222 - 财政年份:2013
- 资助金额:
$ 13.27万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 13.27万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 13.27万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 13.27万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 13.27万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 13.27万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 13.27万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 13.27万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 13.27万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 13.27万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 13.27万 - 项目类别:
Research Grant